Comparative Effects of Enoxaparin and Heparin on Arterial and Venous Clot Lysis with Alteplase in Dogs

Summary

The effects of Enoxaparin with a specific anti-thrombin (anti-IIa) activity of 32 U/mg and a specific anti-factor-XA (anti-Xa) activity of 96 U/mg, and of heparin with a specific anti-IIa and anti-Xa activity of 192 U/mg, on thrombolysis with alteplase (Actilyse®) were compared in a randomized blinded study using a combined arterial and venous thrombosis model in the dog. All dogs received an intravenous bolus of 5 mg/kg lysine-acetyl salicylate and 0.5 mg/kg alteplase over 60 min. Twenty-eight dogs were randomly assigned to seven treatment groups: placebo, Enoxaparin 1.5, 3 or 6 mg/kg, or heparin 0.5, 1 or 2 mg/kg, given as a 50% intravenous bolus and a 50% infusion over 2 h. Steady-state plasma levels ranged from 0.37 to 1.0 anti-IIa U/ml and 0.9 to 3.1 anti-Xa U/ml for Enoxaparin and from 0.4 to 2.3 anti-IIa U/ml and 0.42 to 3.2 anti-Xa U/ml for heparin. The activated thromboplastin time with 6 mg/kg Enoxaparin prolonged to 94 ± 19 s and with 2 mg/kg heparin to >150 s.

The time to reflow was 120 ± 36 min with placebo, 19 ± 5 min with 6 mg/kg Enoxaparin (p = 0.03 vs control), and 22 ± 5 min with 2 mg/kg of heparin (p = 0.03 vs control). Arterial patency, expressed in min reflow during the 180 min observation period correlated significantly with the dose of anticoagulant given (r = 0.73, p = 0.003 for Enoxaparin and r = 0.61, p = 0.012 for heparin). When the dose of anticoagulant was expressed in anti-IIa U/kg, Enoxaparin was significantly more potent than heparin (patency times of 0.62 ± 0.15 and 0.21 ± 0.09 min per anti-IIa U/kg respectively, p = 0.04) but in terms of mg/kg or anti-Xa U/kg both anticoagulants were equipotent.

Venous clot lysis also correlated significantly with the dose of anticoagulant given (r = 0.62, p = 0.011 for Enoxaparin and r = 0.76, p = 0.004 for heparin). When the dose of anticoagulant was expressed in anti-IIa U/kg Enoxaparin was equipotent to heparin, but in terms of mg/kg or anti-Xa U/kg heparin was more potent than Enoxaparin (6 ± 2% lysis per mg/kg Enoxaparin and 35 ± 9% lysis per mg/kg heparin, p= 0.001).

In conclusion, Enoxaparin and heparin enhance arterial and venous clot lysis with alteplase differently; for arterial patency, potency correlates with anti-Xa activity whereas for venous clot lysis potency correlates with anti-IIa activity.

• References

• 1 Cercek B, Lew AS, Hod H, Yano J, Reddy NK, Ganz W. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 1986; 74: 583-587
• 2 Stassen JM, Juhan-Vague I, Alessi MC, De Cock F, Collen D. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator. Thromb Haemostas 1987; 58: 947-950
• 3 Tomaru T, Uchida Y, Nakamura F, Sonoki H, Tsukamatu M, Sugimoto T. Enhancement of arterial thrombolysis with native tissue-type plasminogen activator by pretreatment with heparin or batroxobin: an angioscopic study. Am Heart J 1989; 117: 275-281
• 4 Rapold HJ, Lu HR, Wu Z, Nijs H, Collen D. Requirement of heparin for arterial and thrombolysis with recombinant tissue-type plasminogen activator. Blood 1991; 77: 1020-1024
• 5 Rapold HJ, Kuemmerli H, Weiss M, Baur H, Haeberli A. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989; 79: 980-989
• 6 Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72: 616-620
• 7 Rapold HJ. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation. Lancet 1990; 1: 481-482
• 8 Rapold HJ, de Bono DP, Arnold AER, Arnout J, De Cock F, Collen D, Verstraete M. for the European Cooperative Study Group. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency.and recurrent ischemia. Circulation 1992; 85: 928-934
• 9 Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low-dose aspirin as adjunctive tissue therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433-1437
• 10 Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 1412-1417
• 11 de Bono DP, Simoons ML, Tijssen J, Arnold AER, Betriu A, Burgersdijk C, Lopez BescosL, Mueller E, Pfisterer M, Van de Werf F, Zijlstra F, Verstraete M. for the European Cooperative Study Group. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992; 67: 122-128
• 12 Chesebro JH, Fuster V. Dynamic thrombosis and thrombolysis. Role of antithrombins. Circulation 1991; 83: 1810-1818
• 13 Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991; 83: 1048-1056
• 14 Heras M, Chesebro JH, Penny WJ, Bailey KR, Lam JY, Holmes DR, Reeder GS, Badimon GS, Badimon L, Fuster V. Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation 1988; 78: 654-660
• 15 Badimon L, Lassila R, Badimon J, Vallabhajosula S, Chesebro JH, Fuster V. Residual thrombus is more thrombogenic than severely damaged vessel wall. Circulation 1988; 78 (Suppl. 02) II-119
• 16 Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute plateletthrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657-665
• 17 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-3623
• 18 Rucinski B, Niewiarowski S, James P, Walz DA, Budzynski AZ. Antiheparin proteins secreted by human platelets. Purification, characterization, and radioimmunoassay. Blood 1979; 53: 47-62
• 19 Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
• 20 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin-D-phenylalanyl-L-prolyl-Larginyl chloromethylketon. Proc Natl Acad Sci USA 1988; 85: 3184-3188
• 21 Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990; 81: 219-225
• 22 Nestre M, Uzan A, Sedivy P, Cavero I. Enoxaparin (Clescane, Lovenox), a low molecular weight heparin, enhances t-PA induced coronary thrombus lysis, with low antithrombin effects in anesthetized dogs. Thromb Res. (in press, submitted)
• 23 Ofosu FA, Barrowcliffe IW. Mechanisms of action of low molecular weight heparins and heparinoids. In: Antithrombotic Therapy. Hirsh J. (ed). Clinical Haematology Vol. 3. Baillière Tindall; London: 1990: 505-529
• 24 Levine MN, Hirsh J. Clinical potential of low molecular weigth heparins. In: Antithrombotic Therapy. Hirsh J. (ed). Clinical Haematology Vol. 3. Baillière Tindall; London: 1990: 545-554
• 25 Frydman AM, Bara L, LeRoux Y, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmacokinetics of Enoxaparin, a low molecular weight heparin in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988; 28: 609-618
• 26 Korninger C, Matsuo O, Suy R, Stassen JM, Collen D. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis. J Clin Invest 1982; 69: 573-580
• 27 Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. Circulation 1991; 84: 1216-1234
• 28 Larsen ML, Abildgaard U, Teien AN, Gjesdal K. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA. Thromb Res 1978; 13: 285-288
• 29 Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-416
• 30 Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemostas 1987; 58: 1078-1084